DVA Stock - DaVita Inc.
Unlock GoAI Insights for DVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $12.82B | $12.14B | $11.61B | $11.62B | $11.55B |
| Gross Profit | $4.22B | $3.82B | $3.40B | $3.65B | $3.56B |
| Gross Margin | 32.9% | 31.5% | 29.3% | 31.4% | 30.8% |
| Operating Income | $2.09B | $1.60B | $1.34B | $1.80B | $1.69B |
| Net Income | $936.34M | $691.53M | $560.40M | $978.45M | $773.64M |
| Net Margin | 7.3% | 5.7% | 4.8% | 8.4% | 6.7% |
| EPS | $11.02 | $7.62 | $6.03 | $9.30 | $6.54 |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 6th 2024 | Barclays | Initiation | Equal Weight | $133 |
| August 7th 2023 | UBS | Upgrade | Buy | $142← $100 |
| November 1st 2022 | Deutsche Bank | Downgrade | Hold | $72← $97 |
| October 31st 2022 | UBS | Downgrade | Neutral | $74← $117 |
| August 19th 2022 | UBS | Resumed | Buy | $117← $106 |
| June 21st 2022 | BofA Securities | Reiterated | Underperform | $90← $110 |
Earnings History & Surprises
DVAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $3.34 | — | — | — |
Q4 2025 | Oct 29, 2025 | $3.17 | $2.51 | -20.8% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $2.70 | $2.95 | +9.3% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $1.95 | $2.00 | +2.6% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $2.14 | $2.24 | +4.7% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $2.72 | $2.59 | -4.8% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $2.54 | $2.50 | -1.6% | ✗ MISS |
Q2 2024 | May 2, 2024 | $1.95 | $2.26 | +15.9% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $1.59 | $1.62 | +1.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $2.02 | $2.62 | +29.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $1.69 | $1.91 | +13.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $1.15 | $1.25 | +8.7% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $0.88 | $1.11 | +26.1% | ✓ BEAT |
Q4 2022 | Oct 28, 2022 | $1.65 | $1.45 | -12.1% | ✗ MISS |
Q3 2022 | Aug 1, 2022 | $2.09 | $2.30 | +10.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $1.87 | $1.61 | -13.9% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $1.80 | $2.02 | +12.2% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $2.25 | $2.36 | +4.9% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $2.17 | $2.64 | +21.7% | ✓ BEAT |
Latest News
TD Cowen Maintains Hold on DaVita, Lowers Price Target to $133
➖ NeutralBarclays Maintains Equal-Weight on DaVita, Lowers Price Target to $143
➖ NeutralDaVita Narrows FY2025 Adj EPS Guidance from $10.20-$11.30 to $10.35-$11.15 vs $10.86 Est
➖ NeutralDaVita Q3 Adj. EPS $2.51 Misses $3.22 Estimate, Sales $3.420B Miss $3.428B Estimate
📉 NegativeBarclays Maintains Equal-Weight on DaVita, Lowers Price Target to $149
➖ NeutralB of A Securities Maintains Underperform on DaVita, Lowers Price Target to $140
📉 NegativeDavita Board Increases Share Repurchase Program By $2B
📈 PositiveFrequently Asked Questions about DVA
What is DVA's current stock price?
What is the analyst price target for DVA?
What sector is DaVita Inc. in?
What is DVA's market cap?
Does DVA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DVA for comparison